Petosemtamab (Anti-EGFR/LGR5) is a highly potent bispecific antibody against EGFR (Kd 0.22 nM) and LGR5 (Kd 0.86 nM). It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD.